Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology

Perry, Elaine K.; Morris, Christopher M.; Court, Jennifer A.; Cheng, Anthony V.; Fairbairn, Andrew; McKeith, Ian G.; Irving, Dorothy; Brown, Andrew; Perry, Robert H.

doi:10.1016/0306-4522(94)00410-7

Cited by 351 publications

(177 citation statements)

References 59 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…This finding is in agreement with evidence of reduced [ 3 H] nicotine binding in the SN pars compacta and ventral tegmental area (Perry et al, 1995).…”

Section: Disease Comparisonssupporting

confidence: 92%

“…Significantly reduced 5-[ 125 I]-A-85380 binding in AD compared to controls was also found in the entorhinal cortex, consistent with reports of deficits in [ 3 H]nicotine binding (Court et al, 2001) and [ 3 H]epibatidine binding and a4 subunit protein expression in the neocortex in AD (Martin-Ruiz et al, 1999;Guan et al, 2000). A trend of lower 5-[ 125 I]-A-85380 in thalamic nuclei was seen in AD; however, this did not reach statistical significance confirming earlier reports of no major deficits in thalamic areas in AD (Xuereb et al, 1990;Court et al, 2001 (Perry et al, 1995;MartinRuiz et al, 2000). The relative severity of the reduction of [ 3 H]epibatidine binding in the temporal cortex has been reported to be related to disturbances in consciousness (DOC) seen in some DLB patients, where patients with DOC show higher binding in the temporal cortex, including the entorhinal cortex, than patients showing no DOC (Ballard et al, 2002).…”

Section: Disease Comparisonssupporting

confidence: 87%

“…Reductions in nAChR density have been identified in a number of neurodegenerative disorders including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD) (Rinne et al, 1991;Perry et al, 1995;Court et al, 2000a). In AD, binding assays with [ 3 H]ABT-418 and [ 3 H]epibatidine (Warpman and Nordberg, 1995) and immunochemical analysis (Martin-Ruiz et al, 1999;Wevers et al, 1999;Guan et al, 2000;Burghaus et al, 2000) indicate that the major contributor to loss of nAChRs in cortical areas is the a4 subunit.…”

Section: Introductionmentioning

confidence: 99%

“…In PD, the majority of reports indicate deficits in high-affinity nicotinic agonist binding in both the caudate and putamen (Perry et al, 1990a;Rinne et al, 1991;Aubert et al, 1992a;Court et al, 2000b), in parallel with the decline in dopaminergic markers (Piggott et al, 1999). Reduced [ 3 H]nicotine binding in the substantia nigra (SN) pars compacta and ventral tegmental area has also been reported in PD (Perry et al, 1995). In DLB, losses in [ 3 H]nicotine binding have been reported in the striatum, the SN pars compacta and pars reticulata, and the dorsolateral tegmentum (Perry et al, 1995;Court et al, 2000b).…”

Section: Introductionmentioning

confidence: 99%

“…Reduced [ 3 H]nicotine binding in the substantia nigra (SN) pars compacta and ventral tegmental area has also been reported in PD (Perry et al, 1995). In DLB, losses in [ 3 H]nicotine binding have been reported in the striatum, the SN pars compacta and pars reticulata, and the dorsolateral tegmentum (Perry et al, 1995;Court et al, 2000b).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Pimlott

Piggott

Owens

et al. 2003

Neuropsychopharmacol

151

105

View full text Add to dashboard Cite

“…This finding is in agreement with evidence of reduced [ 3 H] nicotine binding in the SN pars compacta and ventral tegmental area (Perry et al, 1995).…”

Section: Disease Comparisonssupporting

confidence: 92%

Section: Disease Comparisonssupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Pimlott

Piggott

Owens

et al. 2003

Neuropsychopharmacol

151

105

View full text Add to dashboard Cite

Reduced α4β2*–Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease

Meyer¹,

Strecker²,

Kendziorra³

et al. 2009

Arch Gen Psychiatry

142

125

View full text Add to dashboard Cite

There is a broad reduction of alpha4beta2*-nAChR availability in patients with PD without clinically manifest dementia or depression compared with healthy volunteers. Reduced alpha4beta2*-nAChR binding in patients with PD within the subcortical and cortical regions is associated with the severity of mild cognitive or depressive symptoms. These results provide novel in vivo evidence for a role of the cholinergic neurotransmission in psychiatric comorbidity of PD.

show abstract

Pathologic and Nicotinic Receptor Binding Differences Between Mild Cognitive Impairment, Alzheimer Disease, and Normal Aging

Sabbagh¹,

Shah²,

Reid³

et al. 2006

Arch Neurol

View full text Add to dashboard Cite

Background: Neurochemical and pathologic studies show that mild cognitive impairment (MCI) is frequently a transitional state between normal aging and Alzheimer disease (AD). Neuropathologic sample sizes have been limited because relatively few individuals with MCI die before dementia develops. Decreased neocortical nicotinic receptor binding is characteristic of AD but has not been investigated in subjects with MCI.Objective: To assess nicotinic receptor binding and pathologic differences in control subjects with no dementia (ND) and in subjects with clinically and pathologically described MCI or Alzheimer disease.Design: This was a clinicopathologic analysis. Subjects with ND had no demonstrable cognitive or functional impairment. Subjects with MCI met Petersen clinical criteria for single-or multiple-domain amnestic MCI and died before the disorder progressed to AD. Subjects with AD met National Institute for Neurological Diseases and Stroke/Alzheimer's Disease and Related Disorders Association clinical criteria for AD. All subjects underwent a complete diagnostic and semiquantitative neuropathologic examination. Data were examined after both clinical and histopathologic classification of subjects.Setting: Sun Health Research Institute Brain Donation Program, and Arizona Alzheimer Disease Center.Participants: Twenty-one control subjects with ND, 8 subjects with MCI, and 70 subjects with AD, prospectively followed up to autopsy. Main Outcome Measures:Nicotinic acetylcholine receptor binding value, total tangle density, total plaque density, and Braak stage.Results: At the last examination before death, subjects with AD were significantly younger, less educated, and more cognitively and globally impaired compared with subjects with ND. When categorized by clinical diagnosis, MCI was always intermediate between ND and AD. On the whole, MCI was pathologically intermediate between ND and AD for senile plaque density, neurofibrillary tangle density, and Braak stage, but some subjects with MCI lacked neuritic plaques entirely. Binding for nicotinic acetylcholine receptors did not differ between the ND and MCI groups, but it was significantly less in the AD group.Conclusions: Most MCI may be considered a transitional state between ND and AD clinically and neuropathologically, but in some MCI cases there is lack of neuritic plaques, and, therefore, it cannot be considered early AD. Nicotinic receptor binding seems to be lost during the transition from MCI to AD.

show abstract

Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology

Cited by 351 publications

References 59 publications

Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Reduced α4β2*–Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease

Pathologic and Nicotinic Receptor Binding Differences Between Mild Cognitive Impairment, Alzheimer Disease, and Normal Aging

Contact Info

Product

Resources

About